Antiviral treatments with nucleos(t)ide analog (NA) and/or interferon α (IFNα) can reduce the risks of HCC occurrence and recurrence, especially in those with HBV mutations in the core promoter region of the HBV genome [17,18]. Here, IFNA2 is linked to hepatocellular carcinoma.